This medical education event aims to provide HCP's from the Europe, Middle East and Canada regions with up to date knowledge and experience on the practical and real-world management of patients with Liver Diseases, including HCV, HBV, NASH, PSC and other liver diseases such as HCC, Alcoholic Hepatitis, Autoimmune Hepatitis, Hepatitis E etc.

The innovative international 'experience exchange' format aims to allow for comparisons and similarities to be made within the different healthcare systems when dealing patient care, which delegates can take and apply to their own practice. Case-study workshops and other innovative interactive sessions will provide delegates with the chance to engage closely with the experts and each other, gaining advice and finding solutions to specific clinical issues.

The overall objectives of the meeting are detailed below:

HCV

To educate delegates on the importance of identifying at-risk patients and the tools to help simplify the patient care pathway and achieve HCV elimination

To highlight the benefits of a multidisciplinary approach to care, by moving HCV management outside the hepatology setting (e.g. prisons and addiction centres)

To explore various microelimination initiatives, discuss their practicalities and share experiences of microelimination in different settings

To discuss which patients would be most appropriate for specialist care, and when fibrosis assessment is still necessary

Provide information on how the use of SOF/VEL (including safety data) and test and treat approaches can simplify the patient care cascade, as well as highlight the current HCV landscape by discussing the available treatment options according to international guidelines.

To educate delegates about the management of patients who failed DAA treatment, by discussing different treatment options to make it more balanced.

HBV

To provide delegates with the opportunity to discuss HBV management in different patients, e.g.:

Core-positive patients with an HBV reactivation

Patients with normal alanine aminotransferase (ALT)

HDV/HBV coinfected patients

Patients at-risk of hepatocellular carcinoma (HCC)

To discuss whether there is a difference in HCC risk between nucleos(t)ide analogs (NAs) in patients with chronic hepatitis B

NASH

To explore the benefits and challenges of referral pathways to identify patients at risk of advanced fibrosis due to NASH

To explore the recent advances in noninvasive testing to stage at-risk patients and the potential utilisation of these tools in referral pathways

To discuss who should be involved in a multidisciplinary approach to care (e.g. cardiologist, diabetologist, primary care providers)

Other liver diseases